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1. INTRODUCTION {#exd13676-sec-0001}
===============

Psoriasis is a chronic immune‐mediated disease that affects 3.2% of the adult US population[1](#exd13676-bib-0001){ref-type="ref"} and is characterized by scaly red plaques[2](#exd13676-bib-0002){ref-type="ref"} associated with a diminished quality of life.[2](#exd13676-bib-0002){ref-type="ref"}, [3](#exd13676-bib-0003){ref-type="ref"} Psoriasis is associated with multiple comorbidities, including arthritis, diabetes, cardiovascular disease and depression,[4](#exd13676-bib-0004){ref-type="ref"}, [5](#exd13676-bib-0005){ref-type="ref"} as well as decreased life expectancy in patients with severe disease.[6](#exd13676-bib-0006){ref-type="ref"} An increased risk of cancer has been observed among patients with psoriasis compared with the general population.[7](#exd13676-bib-0007){ref-type="ref"} Cohort studies have shown that patients with psoriasis have an increased risk of specific cancers regardless of their treatment, including non‐melanoma skin cancers (NMSCs), lymphohematopoietic cancers and cancers of the respiratory and digestive tracts.[7](#exd13676-bib-0007){ref-type="ref"}, [8](#exd13676-bib-0008){ref-type="ref"}, [9](#exd13676-bib-0009){ref-type="ref"} The interleukin‐12 (IL‐12)/23 inhibitor ustekinumab is an established treatment for psoriasis, and IL‐23--specific inhibitors are among the newest therapies, with promising efficacy and safety profiles (Table [1](#exd13676-tbl-0001){ref-type="table"}; Figure [1](#exd13676-fig-0001){ref-type="fig"}).[10](#exd13676-bib-0010){ref-type="ref"}, [11](#exd13676-bib-0011){ref-type="ref"} IL‐12 and IL‐23 play a central role in T‐cell--mediated immunity and the proinflammatory responses associated with autoimmune conditions.[12](#exd13676-bib-0012){ref-type="ref"}, [13](#exd13676-bib-0013){ref-type="ref"}, [14](#exd13676-bib-0014){ref-type="ref"}, [15](#exd13676-bib-0015){ref-type="ref"}, [16](#exd13676-bib-0016){ref-type="ref"}, [17](#exd13676-bib-0017){ref-type="ref"}, [18](#exd13676-bib-0018){ref-type="ref"} However, in vitro and animal studies have suggested that IL‐12 and IL‐23 may have distinct roles in contributing to protective immune responses to tumors[19](#exd13676-bib-0019){ref-type="ref"}, [20](#exd13676-bib-0020){ref-type="ref"}, [21](#exd13676-bib-0021){ref-type="ref"} and bacterial infections.[12](#exd13676-bib-0012){ref-type="ref"}, [22](#exd13676-bib-0022){ref-type="ref"} Thus, therapies targeted to IL‐12 and IL‐23 carry a theoretical risk of decreased defenses against pathogens and tumor surveillance. A concern for an increased risk of malignancy has been raised with other immunosuppressive therapies used for the treatment of psoriasis, such as anti--tumor necrosis factor (TNF) inhibitors, owing to the role of TNF in tumor growth inhibition.[23](#exd13676-bib-0023){ref-type="ref"} This is a review of the currently available information on the role of IL‐12 and IL‐23 in tumor growth and is written for clinicians who want to understand the potential risk of malignancy associated with blocking IL‐12 and/or IL‐23 in the treatment of psoriasis.

###### 

Inhibitors of IL‐12/23 or IL‐23 licensed or in clinical development for the treatment of psoriasis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Generic name \[compound\] (brand name)                Antibody type                               Mechanism of action                                                                Manufacturer                                                References
  ----------------------------------------------------- ------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ustekinumab\                                          Fully human IgG1κ monoclonal antibody       Binds with high affinity to IL‐12/23p40 subunit                                    Janssen Biotech Inc.                                        Kauffman et al[85](#exd13676-bib-0085){ref-type="ref"}
  \[CNTO‐1275\]\                                                                                                                                                                                                                                   
  (Stelara^®^)                                                                                                                                                                                                                                     

  Briakinumab[a](#exd13676-note-0002){ref-type="fn"}\   Fully human IgG1λ monoclonal antibody       Binds to IL‐12/23p40 subunit                                                       Abbott Laboratories Ltd                                     Fragoulis et al,[86](#exd13676-bib-0086){ref-type="ref"} Panaccione et al[87](#exd13676-bib-0087){ref-type="ref"}
  \[ABT‐874, J‐695\]\                                                                                                                                                                                                                              
  (Ozespa)                                                                                                                                                                                                                                         

  Guselkumab\                                           Fully human IgG1λ monoclonal antibody       Binds to IL‐23p19 subunit                                                          Janssen Biotech Inc.                                        Reich et al,[11](#exd13676-bib-0011){ref-type="ref"} Gordon et al[88](#exd13676-bib-0088){ref-type="ref"}
  \[CNTO 1959\]\                                                                                                                                                                                                                                   
  (Tremfya^™^)                                                                                                                                                                                                                                     

  Tildrakizumab\                                        Humanized mouse IgG1κ monoclonal antibody   Binds with high affinity to IL‐23p19 subunit (297 pmol/L)                          Merck & Co, Inc., and Sun Pharmaceutical Industries, Inc.   Reich et al,[11](#exd13676-bib-0011){ref-type="ref"} Papp et al[89](#exd13676-bib-0089){ref-type="ref"}
  \[MK‐3222, SCH 900222\]\                                                                                                                                                                                                                         
  (Ilumya^™^)                                                                                                                                                                                                                                      

  Risankizumab\                                         Humanized IgG1κ monoclonal antibody         Binds with high affinity to IL‐23p19 subunit (dissociation constant \<10 pmol/L)   Boehringer Ingelheim and AbbVie Inc.                        Krueger et al,[90](#exd13676-bib-0090){ref-type="ref"} Papp et al,[39](#exd13676-bib-0039){ref-type="ref"} Singh et al[91](#exd13676-bib-0091){ref-type="ref"}
  \[ABBV‐066, BI 655066\]                                                                                                                                                                                                                          

  Mirikizumab\                                          Humanized monoclonal antibody               Blocks IL‐23                                                                       Eli Lilly and Company                                       Eli Lilly and Company[92](#exd13676-bib-0092){ref-type="ref"}
  \[LY3074828\]                                                                                                                                                                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ig, immunoglobulin; IL, interleukin.

US and European license applications withdrawn by manufacturer in 2011.[37](#exd13676-bib-0037){ref-type="ref"}

John Wiley & Sons, Ltd

![Structure of IL‐12 and IL‐23 cytokines and receptors. IL, interleukin; Jak, Janus kinase; R, receptor; STAT, signal transducers and activators of transcription; Tyk, tyrosine kinase](EXD-27-737-g001){#exd13676-fig-0001}

2. STRUCTURE AND BIOLOGICAL EFFECTS OF IL‐12 AND IL‐23 IN PSORIASIS {#exd13676-sec-0002}
===================================================================

IL‐12 and IL‐23 are heterodimers, sharing a common p40 (beta chain) subunit that is combined with either a p35 alpha chain (IL‐12) or p19 alpha chain (IL‐23; Figure [1](#exd13676-fig-0001){ref-type="fig"}).[13](#exd13676-bib-0013){ref-type="ref"}, [18](#exd13676-bib-0018){ref-type="ref"} IL‐12 and IL‐23 signal through heterodimeric receptors, both of which contain IL‐12 receptor β1 (IL‐12Rβ1), which is coupled with IL‐12Rβ2 to form the IL‐12 receptor and with IL‐23R to form the IL‐23 receptor.[17](#exd13676-bib-0017){ref-type="ref"}, [18](#exd13676-bib-0018){ref-type="ref"} Signalling, mediated through the Janus kinase--signal transducers and activators of transcription (Jak‐STAT) pathway, ultimately results in IL‐12 and IL‐23 promoting the development of cell‐mediated responses driven by different subsets of T helper (T~H~) cells.[17](#exd13676-bib-0017){ref-type="ref"}, [18](#exd13676-bib-0018){ref-type="ref"}

IL‐12 plays a key role in differentiation, maintenance and activity of immune cell subsets, including T~H~1 cells (which produce interferon‐γ) and natural killer cells (Figure [2](#exd13676-fig-0002){ref-type="fig"}).[12](#exd13676-bib-0012){ref-type="ref"}, [16](#exd13676-bib-0016){ref-type="ref"}, [24](#exd13676-bib-0024){ref-type="ref"} IL‐23 has a key role in maintenance and activity of IL‐17--producing T~H~17 cells and IL‐22--producing T~H~22 cells.[25](#exd13676-bib-0025){ref-type="ref"} In turn, IL‐17 induces activation and proliferation of keratinocytes, which produce inflammatory cytokines, including IL‐23, leading to a self‐amplificatory loop.[26](#exd13676-bib-0026){ref-type="ref"}, [27](#exd13676-bib-0027){ref-type="ref"} Consequently, antibodies targeted to IL‐12 and IL‐23 (p40 inhibitors) affect T~H~1, T~H~17 and T~H~22 responses, whereas those targeted to IL‐23 alone (p19 inhibitors) primarily affect T~H~17 and T~H~22 responses.[26](#exd13676-bib-0026){ref-type="ref"}, [27](#exd13676-bib-0027){ref-type="ref"}

![Biological effects of IL‐12 and IL‐23 and their inhibitors in psoriasis. DC, dendritic cell; IFN, interferon; IL, interleukin; T~H~, T helper; TNF, tumor necrosis factor](EXD-27-737-g002){#exd13676-fig-0002}

3. INHIBITORS OF IL‐12/23 or IL‐23 FOR THE TREATMENT OF PSORIASIS {#exd13676-sec-0003}
=================================================================

The development of anti--IL‐12/23 antibodies was originally initiated based on the observation that mice deficient in the IL‐12p40 subunit (the subunit shared by IL‐12 and IL‐23) and those treated with neutralizing anti--IL‐12p40 antibodies showed resistance to autoimmunity.[15](#exd13676-bib-0015){ref-type="ref"} The discovery of IL‐23[18](#exd13676-bib-0018){ref-type="ref"} followed by the molecular characterization of IL‐23[17](#exd13676-bib-0017){ref-type="ref"} and other murine and genetic studies helped identify the key pathogenic role of IL‐23 in psoriasis, as summarized by Gaffen et al.[25](#exd13676-bib-0025){ref-type="ref"} It is now understood that IL‐12 and IL‐23 act on different components of the chronic inflammatory loop associated with the formation of psoriatic plaques.[28](#exd13676-bib-0028){ref-type="ref"} An association between IL‐12 and psoriasis is supported by the presence of T~H~1 cells and interferon‐γ in psoriatic lesions.[29](#exd13676-bib-0029){ref-type="ref"} However, recent data from a mouse model of psoriasis suggest that IL‐12 may dampen skin inflammation in psoriasis by modulating IL‐23--mediated inflammatory events, decreasing skin invasion by T~H~17 cells and promoting an anti‐inflammatory genetic programme in keratinocytes.[30](#exd13676-bib-0030){ref-type="ref"}

Two antibodies targeting IL‐12/23p40---ustekinumab and briakinumab---have been evaluated as treatments for psoriasis and other immune‐mediated diseases.[31](#exd13676-bib-0031){ref-type="ref"}, [32](#exd13676-bib-0032){ref-type="ref"}, [33](#exd13676-bib-0033){ref-type="ref"}, [34](#exd13676-bib-0034){ref-type="ref"}, [35](#exd13676-bib-0035){ref-type="ref"} Ustekinumab is the only IL‐12/23p40 inhibitor for the treatment of moderate‐to‐severe plaque psoriasis and psoriatic arthritis approved by the Food and Drug Administration (FDA).[36](#exd13676-bib-0036){ref-type="ref"} Clinical development of briakinumab was discontinued, thought to be because of safety concerns reported in the clinical trials, including cardiac events and malignancies.[31](#exd13676-bib-0031){ref-type="ref"}, [37](#exd13676-bib-0037){ref-type="ref"} Guselkumab was the first antibody specifically targeting IL‐23p19 to be approved for the treatment of moderate‐to‐severe psoriasis[38](#exd13676-bib-0038){ref-type="ref"}, and 3 further IL‐23p19 inhibitors are currently in active development for the same indication. Efficacy and safety data have been published for tildrakizumab (phase 3[11](#exd13676-bib-0011){ref-type="ref"}) and risankizumab (phase 2[39](#exd13676-bib-0039){ref-type="ref"}); mirikizumab (LY3074828) is currently entering phase 2 development.[40](#exd13676-bib-0040){ref-type="ref"}

4. MALIGNANCIES REPORTED IN CLINICAL TRIALS {#exd13676-sec-0004}
===========================================

A variety of cancer types have been reported in clinical trials of IL‐12/23 and IL‐23 inhibitors (Table [2](#exd13676-tbl-0002){ref-type="table"}). NMSCs were the most frequently reported malignancies. These are the most common malignancies in humans (albeit not routinely reported to cancer registries), with basal cell carcinomas (BCCs) more common than squamous cell carcinomas (SCCs).[41](#exd13676-bib-0041){ref-type="ref"} A meta‐analysis of observational studies found that the risk of SCCs was increased in patients with psoriasis compared with the general population (standardized incidence ratio \[SIR\] = 5.31, 95% confidence interval \[CI\] = 2.63--10.71) and correlated with patient exposure to 8‐methoxypsoralen--ultraviolet (UV) A therapy for treatment of psoriasis.[9](#exd13676-bib-0009){ref-type="ref"} Risk of BCCs was also increased in patients with psoriasis, but to a lesser extent than SCCs (SIR = 2.00, 95% CI = 1.83--2.20).[9](#exd13676-bib-0009){ref-type="ref"} In trials of ustekinumab for psoriasis, as in the general population,[41](#exd13676-bib-0041){ref-type="ref"} the proportion of BCCs was higher than that of SCCs.[32](#exd13676-bib-0032){ref-type="ref"}, [42](#exd13676-bib-0042){ref-type="ref"}, [43](#exd13676-bib-0043){ref-type="ref"}, [44](#exd13676-bib-0044){ref-type="ref"} However, a pooled analysis of safety data from all briakinumab phase 2 and phase 3 trials and interim data from an open‐label extension trial suggested that the risk of SCC was similar to the risk of BCC in patients treated with briakinumab, which may suggest a relative or absolute increase in the risk of SCC.[45](#exd13676-bib-0045){ref-type="ref"} Concern about the effect of briakinumab on NMSCs was thought to be one of the reasons for discontinuing its development.[31](#exd13676-bib-0031){ref-type="ref"}, [37](#exd13676-bib-0037){ref-type="ref"}

###### 

Reported malignancies in clinical trials of IL‐12/23 and IL‐23 inhibitors in patients with moderate‐to‐severe psoriasis receiving active treatment with an IL‐12/23 OR IL‐23 inhibitor

  Inhibitor                                  Phase           Name                                NCT \#                                         Study length   N                                                                                                      Treatment arms                                          Cases of reported malignancies                 Reference                                                                                                                                                                                                                                                                                             
  ------------------------------------------ --------------- ----------------------------------- ---------------------------------------------- -------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------- ---------------------------------------------- ----------- ------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------- --------------------------------------------------------
  Ustekinumab                                1               Single dose                         --                                             16 wk          18                                                                                                     0.1--5 mg/kg                                                                                                                                                                                                                                                                                                                                       None                                                      Kauffman et al[85](#exd13676-bib-0085){ref-type="ref"}
  2                                          --              00320216                            36 wk                                          320            45 or 90 mg[a](#exd13676-note-0005){ref-type="fn"}                                                     2                                                       1                                              1                                                            None                                                                                                                                                                           Krueger et al[44](#exd13676-bib-0044){ref-type="ref"}     
  3                                          PHOENIX 1       00267969                            76 wk                                          766            45 or 90 mg[a](#exd13676-note-0005){ref-type="fn"}                                                     4                                                                                                      1           1                                                4: thyroid cancer, lentigo maligna, colon cancer, transitional cell carcinoma                                                                                                  Leonardi et al[32](#exd13676-bib-0032){ref-type="ref"}    
  Ext                                        PHOENIX 1 OLE   --                                  \>5 y (264 wk)                                 753            45 or 90 mg                                                                                            13                                                      1                                              5           1                                                9: 3 melanomas (2 in situ, 1 invasive), and 1 each of colon cancer, lymphoma, metastatic pancreatic carcinoma, head/neck cancer, thyroid cancer, transitional cell carcinoma   Kimball et al[43](#exd13676-bib-0043){ref-type="ref"}     
  3                                          PHOENIX 2       00307437                            52 wk                                          1230           45 or 90 mg[a](#exd13676-note-0005){ref-type="fn"}                                                     7[b](#exd13676-note-0006){ref-type="fn"}                                                                           2: hepatocellular carcinoma, SCC of the tongue   Papp et al[33](#exd13676-bib-0033){ref-type="ref"}                                                                                                                                                                                       
  3                                          ACCEPT          00454584                            64 wk                                          903            45 or 90 mg[c](#exd13676-note-0007){ref-type="fn"}                                                     6 + 2[d](#exd13676-note-0008){ref-type="fn"}            1 + 2[d](#exd13676-note-0008){ref-type="fn"}   1           1                                                3: oral neoplasm, chronic lymphocytic leukaemia, mycosis fungoides                                                                                                             Griffiths et al[42](#exd13676-bib-0042){ref-type="ref"}   
  2[e](#exd13676-note-0009){ref-type="fn"}   Dose ranging    02054481                            48 wk                                          166            45 or 90 mg                                                                                                                                                                                                                                                                None                                                                                                                                                                           Papp et al[39](#exd13676-bib-0039){ref-type="ref"}        
  3[f](#exd13676-note-0010){ref-type="fn"}   NAVIGATE        02203032                            60 wk                                          871            45 or 90 mg                                                                                            3                                                       1                                                                                                           2: bile duct cancer, pancreatic carcinoma                                                                                                                                      Langley et al[93](#exd13676-bib-0093){ref-type="ref"}     
  Briakinumab                                2               M05‐736                             00292396                                       12 wk          180                                                                                                    100 or 200 mg[a](#exd13676-note-0005){ref-type="fn"}                                                   1                                                                                                                                                                                                                                           None                                                      Kimball et al[94](#exd13676-bib-0094){ref-type="ref"}
  3                                          M10‐114         00691964                            12 wk                                          347            200--100 mg[a](#exd13676-note-0005){ref-type="fn"} ^,^ [c](#exd13676-note-0007){ref-type="fn"}                                                                                                                                                                             1 malignant melanoma in situ                                                                                                                                                   Gottlieb et al[95](#exd13676-bib-0095){ref-type="ref"}    
  3                                          M10‐315         00710580                            12 wk                                          350            200--100 mg[a](#exd13676-note-0005){ref-type="fn"} ^,^ [c](#exd13676-note-0007){ref-type="fn"}         1                                                                                                                                                                   2: colon cancer, lip neoplasm                                                                                                                                                  Strober et al[96](#exd13676-bib-0096){ref-type="ref"}     
  3                                          M10‐255         00679731                            52 wk                                          317            200--100 mg[g](#exd13676-note-0011){ref-type="fn"}                                                                                                             1                                              1           1                                                2: transitional cell carcinoma, breast neoplasm‐intraductal carcinoma                                                                                                          Reich et al[97](#exd13676-bib-0097){ref-type="ref"}       
  3                                          M06‐890         00570986                            52 wk                                          1465           200--100 mg[a](#exd13676-note-0005){ref-type="fn"}                                                     4                                                       6                                                                                                           4: nasopharyngeal, tonsillar, lung, and colon cancers                                                                                                                          Gordon et al[31](#exd13676-bib-0031){ref-type="ref"}      
  Guselkumab                                 1               Single, ascending dose              00925574                                       24 wk          24                                                                                                     10--300 mg[a](#exd13676-note-0005){ref-type="fn"}                                                                                                                                                                                                                                                                                                  None                                                      Sofen et al[98](#exd13676-bib-0098){ref-type="ref"}
  2                                          X‐PLORE         01483599                            52 wk                                          293            5--200 mg[h](#exd13676-note-0012){ref-type="fn"}                                                                                                                                                                                                                           1 cervical intraepithelial neoplasia                                                                                                                                           Gordon et al[88](#exd13676-bib-0088){ref-type="ref"}      
  3                                          VOYAGE 1        02207231                            48 wk                                          837            100 mg[h](#exd13676-note-0012){ref-type="fn"}                                                          2                                                                                                      1           1                                                                                                                                                                                                                               Blauvelt et al[46](#exd13676-bib-0046){ref-type="ref"}    
  3                                          VOYAGE 2        02207244                            72 wk                                          992            100 mg[h](#exd13676-note-0012){ref-type="fn"}                                                          2                                                       2                                              1                                                                                                                                                                                                                                           Reich et al[10](#exd13676-bib-0010){ref-type="ref"}       
  3                                          NAVIGATE        02203032                            60 wk                                          871            100 mg[i](#exd13676-note-0013){ref-type="fn"}                                                                                                                  1                                                                                                           1 transitional cell carcinoma of the bladder                                                                                                                                   Langley et al[93](#exd13676-bib-0093){ref-type="ref"}     
  Tildrakizumab                              1               Sequential, rising, multiple dose   --                                             16 wk          77                                                                                                     0.05--10 mg/kg[a](#exd13676-note-0005){ref-type="fn"}                                                                                                                                                                                                                                                                                              None                                                      Kopp et al[99](#exd13676-bib-0099){ref-type="ref"}
  2b                                         Dose finding    01225731                            52 wk                                          353            5--200 mg[a](#exd13676-note-0005){ref-type="fn"}                                                                                                                                                                                                                           1 malignant melanoma                                                                                                                                                           Papp et al[89](#exd13676-bib-0089){ref-type="ref"}        
  3                                          reSURFACE 1     01722331                            64 wk[i](#exd13676-note-0013){ref-type="fn"}   772            100 mg, or 200 mg[a](#exd13676-note-0005){ref-type="fn"}                                               3[b](#exd13676-note-0006){ref-type="fn"}                                                                           4: unspecified                                   Reich et al[11](#exd13676-bib-0011){ref-type="ref"}                                                                                                                                                                                      
  3                                          reSURFACE 2     01729754                            52 wk[i](#exd13676-note-0013){ref-type="fn"}   1090           100 mg, or 200 mg[a](#exd13676-note-0005){ref-type="fn"} ^,^ [c](#exd13676-note-0007){ref-type="fn"}   4[b](#exd13676-note-0006){ref-type="fn"}                                                                           4: unspecified                                   Reich et al[11](#exd13676-bib-0011){ref-type="ref"}                                                                                                                                                                                      
  Risankizumab                               1               Single, rising dose                 01577550                                       24 wk          39                                                                                                     0.01--5 mg[a](#exd13676-note-0005){ref-type="fn"}                                                                                                                                                                                                                                                                                                  None reported                                             Krueger et al[90](#exd13676-bib-0090){ref-type="ref"}
  2                                          Dose ranging    02054481                            48 wk                                          166            18, 90, or 180 mg[j](#exd13676-note-0130){ref-type="fn"}                                               2                                                                                                                                                                   1 salivary gland neoplasm                                                                                                                                                      Papp et al[39](#exd13676-bib-0039){ref-type="ref"}        

BCC, basal cell carcinoma; IL, interleukin; NCT, national clinical trial; NMSC, non‐melanoma skin cancer; OLE, open‐label extension; SCC, squamous cell carcinoma.

Blank cells indicate no cases were reported in the publication.
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The clinical evaluation of IL‐23p19 inhibitors is ongoing, and data available thus far are limited. NMSCs have been reported in some clinical trials.[10](#exd13676-bib-0010){ref-type="ref"}, [11](#exd13676-bib-0011){ref-type="ref"}, [39](#exd13676-bib-0039){ref-type="ref"}, [46](#exd13676-bib-0046){ref-type="ref"} Publications about tildrakizumab reported low numbers (7 cases total) of NMSCs but did not differentiate BCCs and SCCs.[11](#exd13676-bib-0011){ref-type="ref"} Two cases of BCCs were reported in the phase 2 trial of risankizumab.[39](#exd13676-bib-0039){ref-type="ref"}

Prostate and breast cancers are the most common internal malignancies in men and women, respectively.[47](#exd13676-bib-0047){ref-type="ref"} Patients with psoriasis have not been found to have a significantly increased risk of prostate cancer compared with the general population,[7](#exd13676-bib-0007){ref-type="ref"}, [8](#exd13676-bib-0008){ref-type="ref"} but the relative risk of breast cancer in patients with psoriasis is less clear. Two analyses showed no significant increased risk,[7](#exd13676-bib-0007){ref-type="ref"}, [8](#exd13676-bib-0008){ref-type="ref"} and one showed a slightly increased risk compared with the general population.[9](#exd13676-bib-0009){ref-type="ref"} Several cases of prostate and breast cancers occurred in trials of ustekinumab,[32](#exd13676-bib-0032){ref-type="ref"}, [42](#exd13676-bib-0042){ref-type="ref"}, [43](#exd13676-bib-0043){ref-type="ref"}, [44](#exd13676-bib-0044){ref-type="ref"} briakinumab[34](#exd13676-bib-0034){ref-type="ref"} and guselkumab.[10](#exd13676-bib-0010){ref-type="ref"}, [46](#exd13676-bib-0046){ref-type="ref"} These malignancy events reported in clinical trials do not prove causation but do suggest a possible biological relationship that may trigger further investigation.[48](#exd13676-bib-0048){ref-type="ref"}

5. MALIGNANCIES REPORTED IN POSTMARKETING SAFETY DATA {#exd13676-sec-0005}
=====================================================

Ustekinumab, which has been approved since 2009, is currently the only IL‐12/23 or IL‐12 inhibitor with postmarketing safety data. The prescribing information (PI) for ustekinumab contains a general warning that it "may increase risk of malignancy," based on the observations that (i) NMSCs were reported in 1.5% of patients and malignancies excluding NMSCs (non‐NMSCs) were reported in 1.7% of patients among patients treated with ustekinumab (3.2 years' median follow‐up); (ii) the most frequently observed non‐NMSCs were prostate, melanoma, colorectal and breast cancers, but they were similar in type and number to those expected in the general US population when adjusted for age, gender and race; and (iii) rapid appearance of multiple cutaneous SCCs was found in postmarketing reports among patients receiving ustekinumab who had pre‐existing risk factors for developing NMSC.[36](#exd13676-bib-0036){ref-type="ref"} The concerns raised in the ustekinumab PI are in line with an analysis of postmarketing safety data reported to the FDA, which found that patients treated with ustekinumab were 15 times more likely to report a case of cancer than were patients treated with apremilast, a phosphodiesterase 4 (PDE‐4) inhibitor.[49](#exd13676-bib-0049){ref-type="ref"} Furthermore, a safety signal was detected in a study of data from the FDA Adverse Event Reporting System database, which indicated that ustekinumab may be associated with several malignancies, including B‐cell lymphoma; epithelioid sarcoma; and lung, oesophageal, ovarian, renal, testis and thyroid cancers.[50](#exd13676-bib-0050){ref-type="ref"}

In contrast, an analysis of data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) showed that patients with psoriasis treated with ustekinumab had numerically fewer non‐NMSCs (0.48/100 patient‐years \[PYs\]) than did patients treated with infliximab, a monoclonal antibody directed at TNF (0.79/100 PYs) or any other biologics (0.73/100 PYs) or non‐biologics (0.84/100 PYs).[51](#exd13676-bib-0051){ref-type="ref"} Results from an analysis of the German Psoriasis Registry (PsoBest) showed similar rates of malignancies excluding NMSCs in patients receiving systemic therapies (0.46/100 PYs) or biologics (0.49/100 PYs), with no relevant differences between therapies.[52](#exd13676-bib-0052){ref-type="ref"} Evidence from controlled clinical trials and registries indicates that ustekinumab is well tolerated, with rates of overall mortality and malignancy comparable with those expected in the general population.[32](#exd13676-bib-0032){ref-type="ref"}, [33](#exd13676-bib-0033){ref-type="ref"}, [53](#exd13676-bib-0053){ref-type="ref"}, [54](#exd13676-bib-0054){ref-type="ref"} Although the postmarketing pharmacovigilance studies mentioned previously were not designed to study causality or to quantify increased cancer risk associated with specific therapies,[49](#exd13676-bib-0049){ref-type="ref"}, [50](#exd13676-bib-0050){ref-type="ref"} they can be helpful to identify safety signals that may be relevant to the advancement of overall patient safety.[55](#exd13676-bib-0055){ref-type="ref"} Postmarketing safety data are not yet available for tildrakizumab, guselkumab or risankizumab. Long‐term data are needed to identify any potential associations between IL‐23 inhibitors and malignancies.

Clinical trials detect adverse events during trials of relatively short duration. For example, the trials of IL‐12/23 and IL--23 inhibitors summarized in Table [2](#exd13676-tbl-0002){ref-type="table"} varied in duration from 12 to 76 weeks. Consequently, drugs are usually made available for public use before rare but potentially serious adverse reactions have been identified and their probabilities quantified.[48](#exd13676-bib-0048){ref-type="ref"} Although NMSCs may develop within weeks to months[56](#exd13676-bib-0056){ref-type="ref"} and are relatively easy to detect by visual inspection, other malignancies may take longer to be discovered. Thus, the incidence of internal malignancy, and even NMSCs, in a clinical trial may not be a good indicator of a drug\'s long‐term effect on malignancy. Malignancies that occur infrequently or develop slowly may only be detected in postmarketing evaluations, making them a critical element of drug safety monitoring efforts. An effect on pre‐existing malignancies is difficult to assess as most trials exclude these patients from receiving systemic immunosuppressive drugs. For example, trials for ustekinumab, briakinumab, guselkumab, tildrakizumab and risankizumab all excluded patients with a pre‐existing malignancy in the preceding 5 years (except fully treated BCCs or SCCs of the skin and/or fully treated cervical carcinoma in situ).[10](#exd13676-bib-0010){ref-type="ref"}, [11](#exd13676-bib-0011){ref-type="ref"}, [31](#exd13676-bib-0031){ref-type="ref"}, [32](#exd13676-bib-0032){ref-type="ref"}, [39](#exd13676-bib-0039){ref-type="ref"}, [46](#exd13676-bib-0046){ref-type="ref"}

6. RISK OF MALIGNANCY IN HUMANS WITH GENETIC TRAITS SIMULATING NEUTRALIZATION OF IL‐12 AND/OR IL‐23 {#exd13676-sec-0006}
===================================================================================================

In the first report of cancer in a patient with IL‐12Rβ1 deficiency (the receptor subunit required to bind the p40 subunit shared by IL‐12 and IL‐23), the patient developed oesophageal SCC at age 25 years and died at age 29 years, an age at which this cancer is exceedingly rare (Table [3](#exd13676-tbl-0003){ref-type="table"}).[57](#exd13676-bib-0057){ref-type="ref"} Additional studies of IL‐12 genetic deficiencies have investigated whether such deficiencies are associated with increased likelihood of infections and cancer.[58](#exd13676-bib-0058){ref-type="ref"}, [59](#exd13676-bib-0059){ref-type="ref"} Genomewide association studies have shown that polymorphisms in genes encoding the IL‐12p40 subunit or the IL‐12p35 subunit, which result in a decreased biological effect of IL‐12, are linked to increased susceptibility to oesophageal cancer,[60](#exd13676-bib-0060){ref-type="ref"} osteosarcoma,[61](#exd13676-bib-0061){ref-type="ref"} bladder cancer[62](#exd13676-bib-0062){ref-type="ref"} and prostate cancer,[63](#exd13676-bib-0063){ref-type="ref"} as well as susceptibility to and/or severity of cervical cancer.[64](#exd13676-bib-0064){ref-type="ref"} Reports of genetic deficiencies simulating a deficiency in the IL‐23--signalling pathway are limited. Several genomewide association studies have been conducted in Chinese populations; they show that variants of *IL‐23R*, the subunit specific for the IL‐23 receptor, are associated with a significantly reduced risk of gastric cancer,[65](#exd13676-bib-0065){ref-type="ref"} but with a significantly increased risk of oesophageal cancer,[66](#exd13676-bib-0066){ref-type="ref"} hepatocellular carcinoma[67](#exd13676-bib-0067){ref-type="ref"} and acute myeloid leukaemia.[68](#exd13676-bib-0068){ref-type="ref"} However, the effect of these *IL‐23R* variants on the function of IL‐23 (eg, gain, loss or no effect) was not specifically described in the studies. Taken together, these findings might lead to the hypothesis that IL‐12/23 inhibitors have the potential to increase the risk of these cancers. However, a limitation of genomewide association studies is that they are not designed to investigate the causal relationship between a specific polymorphism and an increased cancer risk. For example, although several studies had shown that the TNF‐238 polymorphism increased cancer risk, a meta‐analysis of 34 studies did not find a significant association between this polymorphism and increased cancer risk.[69](#exd13676-bib-0069){ref-type="ref"}

###### 

IL‐12/23 and IL‐23 genetic deficiencies associated with increased risk of cancer

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene mutation or polymorphism                                   Effect on IL‐12 and/or IL‐23                                                Effect on malignancy                                                                                                                                                                                                   Potential implications for therapy with IL‐12/23 or IL‐23 inhibitors
  --------------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------
  *IL‐12R*β*1* homozygous deficiency case report                  Loss of IL‐12 and IL‐23 functions                                           Oesophageal squamous cell carcinoma at age 25 y, relapse and death at age 29 y[57](#exd13676-bib-0057){ref-type="ref"}                                                                                                 IL‐12/23 inhibitors may increase risk of oesophageal cancer

  *IL‐12R*β*1* polymorphism: 378 GG/GC vs CC                      Decreased\                                                                  Increased risk of oesophageal cancer[60](#exd13676-bib-0060){ref-type="ref"}                                                                                                                                           IL‐12/23 inhibitors may increase risk of oesophageal cancer
                                                                  IL‐12 levels                                                                                                                                                                                                                                                                                       

  *IL‐12B* (IL‐12p40) polymorphisms:\                             Decreased\                                                                  Increased risk of osteosarcoma[61](#exd13676-bib-0061){ref-type="ref"} and oesophageal[60](#exd13676-bib-0060){ref-type="ref"} and prostate[63](#exd13676-bib-0063){ref-type="ref"} cancers                            IL‐12/23 inhibitors may increase risk of osteosarcomas and bladder, cervical, oesophageal and prostate cancers
  rs321227 AC/CC or CC vs AA, or C vs A                           IL‐12 levels                                                                                                                                                                                                                                                                                       

  1188 AC vs AA                                                   Increased risk of bladder cancer[62](#exd13676-bib-0062){ref-type="ref"}                                                                                                                                                                                                                           

  rs2569254 GG vs AA                                              Increased risk of cervical cancer[64](#exd13676-bib-0064){ref-type="ref"}                                                                                                                                                                                                                          

  *IL‐12A* (IL‐12p35) polymorphisms: rs568408 GA/AA or GA vs GG   Decreased\                                                                  Increased risk of oesophageal cancer[60](#exd13676-bib-0060){ref-type="ref"} and osteosarcoma[61](#exd13676-bib-0061){ref-type="ref"}                                                                                  IL‐12/23 inhibitors may increase risk of osteosarcomas and oesophageal cancer in specific patient populations
                                                                  IL‐12 levels                                                                                                                                                                                                                                                                                       

  *IL‐23R* polymorphisms:\                                        Loss of IL‐23 function                                                      Increased risk of oesophageal cancer,[66](#exd13676-bib-0066){ref-type="ref"} hepatocellular carcinoma,[67](#exd13676-bib-0067){ref-type="ref"} and acute myeloid leukaemia[68](#exd13676-bib-0068){ref-type="ref"}\   IL‐23 inhibitors may affect cancer risk of some cancers in specific patient populations\
  rs6682925 TC/CC or TG/GG or T\>C( )rs1884444n T\>G                                                                                          No association with risk of gastric cancer[65](#exd13676-bib-0065){ref-type="ref"}\                                                                                                                                    IL‐23 inhibitors may decrease risk of gastric cancer
                                                                                                                                              Decreased risk of gastric cancer[65](#exd13676-bib-0065){ref-type="ref"}                                                                                                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IL, interleukin; R, receptor.

John Wiley & Sons, Ltd

7. RISK OF MALIGNANCY IN ANIMAL MODELS SIMULATING NEUTRALIZATION OF IL‐12 AND/OR IL‐23 {#exd13676-sec-0007}
======================================================================================

The malignancy data from animal models of IL‐23 deficiency are conflicting. Mice that had lost IL‐23 function via deficiencies in either *IL‐23p19* or *IL‐23R* or by treatment with antibodies to IL‐23p19 showed resistance to skin tumor growth/development (Table [4](#exd13676-tbl-0004){ref-type="table"}).[20](#exd13676-bib-0020){ref-type="ref"} IL‐23--deficient mice[70](#exd13676-bib-0070){ref-type="ref"} and mice treated with anti--IL‐23p19[71](#exd13676-bib-0071){ref-type="ref"} have also been shown to have an increased resistance to melanoma‐induced lung metastases. Furthermore, in this model of melanoma‐induced metastases, anti--IL‐23 antibody used in combination with IL‐2 or anti‐erbB2 antibody significantly inhibited subcutaneous growth of established mammary carcinomas and suppressed established and spontaneous lung metastases.[71](#exd13676-bib-0071){ref-type="ref"} Deficiencies in *IL‐23p19* or *IL‐23R* also resulted in decreased tumor multiplicity and growth in a mouse model of colorectal tumors.[72](#exd13676-bib-0072){ref-type="ref"} These findings suggest that IL‐23p19 inhibitors might prevent the growth and/or enhance the rejection of some tumors, possibly via effects on IL‐22, which has been implicated in the development of epithelial tumors.[73](#exd13676-bib-0073){ref-type="ref"}, [74](#exd13676-bib-0074){ref-type="ref"} A number of studies have found that increased levels of IL‐23 are associated with unfavourable outcomes in various malignancies in humans.[75](#exd13676-bib-0075){ref-type="ref"}, [76](#exd13676-bib-0076){ref-type="ref"}, [77](#exd13676-bib-0077){ref-type="ref"}, [78](#exd13676-bib-0078){ref-type="ref"}, [79](#exd13676-bib-0079){ref-type="ref"} In contrast, other studies suggest that IL‐23p19 deficiency might enhance the risk of certain cancers. For example, IL‐23--deficient mice demonstrated an increased risk of development of chemically induced melanoma.[80](#exd13676-bib-0080){ref-type="ref"} However, in a model of UV radiation, IL‐23--deficient mice demonstrated both an increased risk of developing sarcoma and a decreased risk of developing epithelial tumors compared with wild‐type mice.[19](#exd13676-bib-0019){ref-type="ref"} Further studies are needed to confirm this finding.

###### 

Malignancies in murine models of IL‐23 deficiency

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model                                                                            Effect on IL‐23                   Tumor‐promotion strategy                                   Effect on malignancy vs controls                                                                        Potential therapeutic implications for IL‐23 inhibitors
  -------------------------------------------------------------------------------- --------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------
  Treatment with anti--IL‐23p19 antibody[20](#exd13676-bib-0020){ref-type="ref"}   Loss of IL‐23 function            Intradermal injection of skin tumor cells                  Faster rejection of tumor cells and decreased tumor formation                                           May prevent tumor growth and enhance tumor rejection

  Treatment with anti--IL‐23p19 antibody[71](#exd13676-bib-0071){ref-type="ref"}   Loss of IL‐23 function            Experimental and spontaneous models of lung metastases\    Early suppression of lung metastases and modest inhibition of primary tumors with subcutaneous growth   May prevent tumor growth and metastasis
                                                                                                                     SC injection of thymoma cells                                                                                                                                      

  *IL‐23p19* ^−/−\[^ [20](#exd13676-bib-0020){ref-type="ref"} ^\]^                 Loss of IL‐23 function            Chemical carcinogenesis\                                   Resistance to developing skin papillomas\                                                               May reduce risk of skin cancer\
                                                                                                                     Intradermal injection of skin tumor cells                  Resistance to developing tumors                                                                         May prevent tumor growth and enhance tumor rejection

  *IL‐23p19* ^−/−\[^ [70](#exd13676-bib-0070){ref-type="ref"} ^\]^                 Loss of IL‐23 function            Experimental model of lung metastases                      Increased resistance to formation of lung metastases                                                    May prevent tumor growth and enhance tumor rejection

  *IL‐23p19* ^−/−\[^ [72](#exd13676-bib-0072){ref-type="ref"} ^\]^                 Loss of IL‐23 function            Colorectal tumorigenesis in genetically predisposed mice   Decreased tumor number and growth                                                                       May prevent tumor growth and enhance tumor rejection

  *IL‐23p19* ^−/−\[^ [19](#exd13676-bib-0019){ref-type="ref"} ^\]^                 Loss of IL‐23 function            Skin UV radiation                                          Increased probability of skin tumor development                                                         May increase risk of UV radiation--induced skin cancer

  *IL‐23p19* ^−/−\[^ [80](#exd13676-bib-0080){ref-type="ref"} ^\]^                 Loss of IL‐23 function            Chemically induced melanoma\                               Increased number and size of melanomas\                                                                 May increase risk of melanoma\
                                                                                                                     Chemically induced epithelial tumor                        Resistance to tumor development                                                                         May decrease risk of epithelial tumors

  *IL‐23R* ^−/−\[^ [20](#exd13676-bib-0020){ref-type="ref"} ^\]^                   Loss of IL‐23 receptor function   Intradermal injection of tumor cells                       Resistance to tumor development                                                                         May prevent tumor growth and enhance tumor rejection

  *IL‐23R* ^−/−\[^ [72](#exd13676-bib-0072){ref-type="ref"} ^\]^                   Loss of IL‐23 receptor function   Colorectal tumorigenesis in genetically predisposed mice   Decreased tumor number and growth                                                                       May prevent tumor growth and enhance tumor rejection
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IL, interleukin; SC, subcutaneous; UV, ultraviolet.

John Wiley & Sons, Ltd

Similarly, the studies on IL‐12 also show conflicting data. Several studies of mice with IL‐12--specific loss of function via deficiency in *IL‐12p35* [20](#exd13676-bib-0020){ref-type="ref"} or *IL‐12R*β*2* [81](#exd13676-bib-0081){ref-type="ref"} showed an increased risk of tumor development (Table [5](#exd13676-tbl-0005){ref-type="table"}), but, in models of UV radiation[19](#exd13676-bib-0019){ref-type="ref"} or chemically induced melanomas,[80](#exd13676-bib-0080){ref-type="ref"} *IL‐12p35*--deficient mice had the same risk of induced skin tumors as did their wild‐type counterparts.

###### 

Malignancies in murine models of IL‐12 deficiency

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model                                                                Effect on IL‐12                   Tumor‐promotion strategy                    Effect on malignancy vs controls                                                                                              Potential therapeutic implications for IL‐12 inhibitors
  -------------------------------------------------------------------- --------------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------
  *IL‐12p35* ^−/−\[^ [83](#exd13676-bib-0083){ref-type="ref"} ^\]^     Loss of IL‐12 function            Spontaneous tumor development               No effect                                                                                                                     No impact on malignancy

  *IL‐12p35* ^−/−\[^ [20](#exd13676-bib-0020){ref-type="ref"} ^\]^     Loss of IL‐12 function            Chemical carcinogenesis\                    Earlier and more frequent skin papillomas\                                                                                    May increase risk of skin cancer
                                                                                                         Intradermal injection of skin tumor cells   Increased incidence of skin tumors                                                                                            

  *IL‐23p35* ^−/−\[^ [70](#exd13676-bib-0070){ref-type="ref"} ^\]^     Loss of IL‐12 function            Experimental model of lung metastases       Increased formation of lung metastases                                                                                        May increase growth and reduce tumor rejection

  *IL‐12p35* ^−/−\[^ [100](#exd13676-bib-0100){ref-type="ref"} ^\]^    Loss of IL‐12 function            Skin UV radiation                           Increased number of skin tumors                                                                                               May increase risk of skin cancer

  *IL‐12p35* ^−/−\[^ [19](#exd13676-bib-0019){ref-type="ref"} ^\]^     Loss of IL‐12 function            Skin UV radiation                           No increased probability of skin tumor development                                                                            May not affect risk of UV radiation--induced skin cancer

  *IL‐12p35* ^−/−\[^ [80](#exd13676-bib-0080){ref-type="ref"} ^\]^     Loss of IL‐12 function            Chemically induced melanomas\               Reduced number and size of melanomas\                                                                                         May reduce risk of melanoma\
                                                                                                         Chemically induced epithelial tumor         Increased tumor development                                                                                                   May increase risk of epithelial tumors

  *IL‐12R*β*2* ^−/−\[^ [81](#exd13676-bib-0081){ref-type="ref"} ^\]^   Loss of IL‐12 receptor function   Spontaneous                                 Increased susceptibility to spontaneous tumor formation, half of aged mice developed plasmacytoma or lung epithelial tumors   May increase risk of cancer
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IL, interleukin; UV, ultraviolet.

John Wiley & Sons, Ltd

Mouse models with loss of function in both IL‐12 and IL‐23 via IL‐12/23p40 deficiency or treatment with anti--IL‐12/23p40 antibodies showed an increase,[20](#exd13676-bib-0020){ref-type="ref"}, [21](#exd13676-bib-0021){ref-type="ref"}, [80](#exd13676-bib-0080){ref-type="ref"} a decrease[82](#exd13676-bib-0082){ref-type="ref"} or no difference[83](#exd13676-bib-0083){ref-type="ref"} in tumor development (Table [6](#exd13676-tbl-0006){ref-type="table"}).

###### 

Malignancies in murine models of IL‐12/23p40 deficiency

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model                                                                                 Effect on IL‐12/23                 Tumor‐promotion strategy                                 Effect on malignancy vs controls                     Potential therapeutic implications for IL‐12/23p40 inhibitors
  ------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------
  Treatment with anti--IL‐12/23p40 antibodies[20](#exd13676-bib-0020){ref-type="ref"}   Loss of IL‐12 and IL‐23 function   Intradermal injection of skin tumor cells                Increased number and size of faster‐growing tumors   May increase risk of cancer, tumor growth, and metastases

  Treatment with anti--IL‐12p40 antibody[71](#exd13676-bib-0071){ref-type="ref"}        Loss of IL‐12 and IL‐23 function   Experimental and spontaneous models of lung metastases   No effect                                            No impact on malignancy

  *IL‐12/23p40* ^−/−\[^ [20](#exd13676-bib-0020){ref-type="ref"} ^\]^                   Loss of IL‐12 and IL‐23 function   Chemical carcinogenesis\                                 Resistance to developing skin papillomas\            May reduce risk of skin cancer\
                                                                                                                           Intradermal injection of skin tumor cells                Increased tumor incidence                            May increase risk of skin cancer

  *IL‐23p40* ^−/−\[^ [70](#exd13676-bib-0070){ref-type="ref"} ^\]^                      Loss of IL‐12 and IL‐23 function   Experimental model of lung metastases                    No effect                                            No impact on malignancy

  *IL‐12/23p40* ^−/−\[^ [21](#exd13676-bib-0021){ref-type="ref"} ^\]^                   Loss of IL‐12 and IL‐23 function   Skin UV radiation                                        Increased skin tumor development                     May increase risk of UV radiation--induced skin carcinogenesis

  *IL‐12/23p40* ^−/−\[^ [82](#exd13676-bib-0082){ref-type="ref"} ^\]^                   Loss of IL‐12 and IL‐23 function   Chemically induced skin tumors                           Resistance to skin tumor development                 May reduce risk of skin cancer

  *IL‐12/23p40* ^−/−\[^ [80](#exd13676-bib-0080){ref-type="ref"} ^\]^                   Loss of IL‐12 and IL‐23 function   Chemically induced melanomas\                            Increased number and size of melanomas\              May increase risk of melanoma\
                                                                                                                           Chemically induced epithelial tumor                      Increased number of epithelial tumors                May increase risk of epithelial tumors
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IL, interleukin; UV, ultraviolet.

John Wiley & Sons, Ltd

8. CONCLUSIONS {#exd13676-sec-0008}
==============

Patients with psoriasis and/or receiving treatment for psoriasis have an increased risk of cancer.[8](#exd13676-bib-0008){ref-type="ref"}, [9](#exd13676-bib-0009){ref-type="ref"}, [49](#exd13676-bib-0049){ref-type="ref"}, [84](#exd13676-bib-0084){ref-type="ref"} Inhibitors of IL‐12/23 and IL‐23 are effective treatment approaches for psoriasis.[36](#exd13676-bib-0036){ref-type="ref"}, [38](#exd13676-bib-0038){ref-type="ref"} Existing data provide evidence to support an association between impaired IL‐12 and/or IL‐23 signalling and both tumor growth and resistance to tumor growth, although the nature of these relationships is not fully understood. Long‐term postmarketing safety evaluations of agents targeting IL‐12/23 and IL‐23 are needed to fully appreciate the associated malignancy risk. The implications for therapeutic inhibition of IL‐12/23 or IL‐23 remain uncertain, although monitoring of patients for NMSC and malignancy seems warranted.
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